News
25 October 2019
Renewed promise for early Alzheimer’s drug signals potential for Cambridge Cognition’s assessment so
Following a consultation with the U.S. Food and Drug Administration (FDA), Biogen and Eisai have announced plans to pursue regulatory approval for aducanumab, which would be the first therapy to tackle clinical decline in early Alzheimer's disease. If successful, this presents an opportunity for Cambridge Cognition whose CANTABTM assessments are specifically sensitive to the early cognitive decline during Alzheimer's disease.
Read on
14 August 2019
Dr. Nick Kerton
Cambridge Cognition Holdings is deeply saddened to report the death of Nick Kerton, the Company’s former Chief Executive Officer and Non-executive Director, after a long fight with cancer.
Read on
12 August 2019
Cambridge Cognition expands further into Chinese market and initial university contract
Cambridge Cognition is pleased to announce its expansion into the Chinese market with the Company’s Cambridge Neuropsychological Test Automated Battery (“CANTAB”) computerised assessments. This move strengthens the Company’s global position, having announced a major opportunity in India earlier this year.
Read on
19 July 2019
New Commercial Partnership and Further Scientific Validation for NeuroVocalix
Cambridge Cognition is pleased to announce the second commercial partnership with a leading pharmaceutical company, for its NeuroVocalixTM platform. NeuroVocalixTM is a unique voice biomarker technology and the product was launched last year and recently presented ground-breaking demonstrable evidence of the potential at a major global Alzheimer’s conference.
Read on
1 July 2019
Cambridge Cognition appoints Non-Executive Director
Cambridge Cognition today announced the appointment of Debra Leeves as a Non-Executive Director with immediate effect.
Read on
24 May 2019
NHS Bedfordshire CCG rolls out CANTAB Mobile to 50 practices following successful pilot study
We’re pleased to announce that NHS Bedfordshire Clinical Commissioning Group (CCG) is introducing our iPad-based memory assessment tool into 50 general practices.